The New Generation of Liquid Intravenous Immunoglobulin Formulations in Patient Care: A Comparison of Intravenous Immunoglobulins
Author:
- 1 September 2010
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 122 (5) , 176-184
Abstract
Intravenous immunoglobulin (IGIV) replacement therapy is the standard of care for primary immunodeficiencies with impaired humoral immunity. It is also the immunomodulatory therapy of choice for some types of neuroimmunologic and autoimmune hematologic disorders and for immunomodulation in bone marrow and some solid organ transplants. Currently available IGIV products include older lyophilized formulations, 5% liquid products, and newer, liquid, ready-to-use, 10% formulations. Differences in the formulations, manufacturing processes, excipients, pH, and other physicochemical properties of IGIV products may affect their clinical efficacy and tolerability. Among at-risk patients, the possibility of serious complications such as renal insufficiency, heart failure, thrombotic events, and immunological reactions may be increased if an IGIV formulation has sugar as a stabilizer, has high sodium or immunoglobulin A (IgA) content, or is hyperosmolar. The 10% liquid formulations may offer advantages because of their lower IgA concentrations, optimal pH, glycine or proline stabilizers, low sodium content, and lower osmolality. Liquid formulations are more convenient for patients and health care providers due to shorter infusion times and easier preparation and administration.Keywords
This publication has 62 references indexed in Scilit:
- The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice GuidelineTransfusion Medicine Reviews, 2010
- Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndromeAnnals of Neurology, 2009
- Investigations of prion and virus safety of a new liquid IVIG productBiologicals, 2008
- Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and ImmunologyJournal of Allergy and Clinical Immunology, 2006
- Clinical uses of intravenous immunoglobulinClinical and Experimental Immunology, 2005
- Practice parameter for the diagnosis and management of primary immunodeficiencyAnnals of Allergy, Asthma & Immunology, 2005
- Subcutaneous immunoglobulin replacement in primary immunodeficienciesClinical Immunology, 2004
- Utility of Intravenous Immune Globulin in Kidney Transplantation: Efficacy, Safety, and Cost ImplicationsAmerican Journal of Transplantation, 2003
- Hypogammaglobulinemia after heart transplantation: impact of pre‐emptive use of immunoglobulin replacement (CytoGam®) on infection and rejection outcomesTransplant Infectious Disease, 2001
- Efficacy of Intravenous Immunoglobulin in Primary Humoral Immunodeficiency DiseaseAnnals of Internal Medicine, 1984